Back
Astellas Pharma 10K Form
Sell
46
ALPMY
Astellas Pharma
Last Price:
11.53
Seasonality Move:
1.12%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
10K form not available
Receive ALPMY News And Ratings
See the #1 stock for the next 7 days that we like better than ALPMY
ALPMY Financial Statistics
Sales & Book Value
| Annual Sales: | $11.11B |
|---|---|
| Cash Flow: | $-76.58M |
| Price / Cash Flow: | 35.56 |
| Annual Sales: | $5.88 |
| Price / Book: | 1.94 |
Profitability
| EPS (TTM): | 0.05830 |
|---|---|
| Net Income (TTM): | $105.19M |
| Gross Margin: | $9.09B |
| Return on Equity: | 0.97% |
| Return on Assets: | 0.47% |
Astellas Pharma Earnings Forecast
Key Astellas Pharma Financial Ratios
- The Gross Profit Margin over the past 21 years for ALPMY is 81.76%.
- The Selling, General & Administrative Expenses for ALPMY have been equal to 46.15% of Gross Profit Margin.
- The Research & Development expenses have been 18.34% of Revenue.
- The Interest Expense is 70.43% of Operating Income.
- The Net Earning history of ALPMY is 1.06% of Total Revenues.
- Per Share Earnings over the last 21 years have been positive in 10 years.
Astellas Pharma Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | OTCM |
|---|---|
| Industry: | Pharmaceuticals |
| Sector: | Health Care |
| Current Symbol: | ALPMY |
| Website: | astellas.com |
Debt
| Debt-to-Equity Ratio: | 0.58 |
|---|---|
| Current Ratio: | 0.93 |
| Quick Ratio: | 0.71 |
Price-to-Earnings
| Trailing P/E Ratio: | 173.86 |
|---|---|
| Forward P/E Ratio: | 0 |
ALPMY Technical Analysis vs Fundamental Analysis
Sell
46
Astellas Pharma (ALPMY)
is a Sell
Is Astellas Pharma a Buy or a Sell?
-
Astellas Pharma stock is rated a Sell
The current Astellas Pharma [ALPMY] share price is $11.41. The Score for ALPMY is 46, which is 8% below its historic median score of 50, and infers higher risk than normal.